- Home
- CFR vs IBRX Comparison
CFR vs IBRX Comparison
Compare CFR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | IBRX |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | 6008 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CFR | IBRX |
|---|---|---|
| Price | $140.07 | $7.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $142.31 | $12.57 |
| AVG Volume (30 Days) | 433.7K | ★ 22.6M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $9.72 | $88.59 |
| Revenue Next Year | $4.70 | $131.15 |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $101.76 | $1.83 |
| 52 Week High | $148.97 | $12.43 |
Technical Indicators
Market Signals| Indicator | CFR | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 44.93 |
| Support Level | $124.16 | $5.89 |
| Resistance Level | $140.27 | $8.28 |
| Average True Range (ATR) | 2.67 | 0.94 |
| MACD | 0.99 | -0.19 |
| Stochastic Oscillator | 98.70 | 18.50 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of December 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.